MA30624B1 - Vaccin anti-grippal - Google Patents
Vaccin anti-grippalInfo
- Publication number
- MA30624B1 MA30624B1 MA31612A MA31612A MA30624B1 MA 30624 B1 MA30624 B1 MA 30624B1 MA 31612 A MA31612 A MA 31612A MA 31612 A MA31612 A MA 31612A MA 30624 B1 MA30624 B1 MA 30624B1
- Authority
- MA
- Morocco
- Prior art keywords
- influenza
- pandemic
- outbreak
- tocopherol
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La présente invention concerne des formulations de vaccin antigrippal monovalent et des régimes de vaccination d'immunisation contre la grippe, leur utilisation médicale, en particulier leur utilisation pour augmenter les réponses immunitaires à divers antigènes, et leurs procédés de préparation. L'invention concerne en particulier des compositions immunogènes antigrippales monovalentes comprenant un antigène grippal ou une préparation d'antigène provenant de la souche du virus de la grippe qui est associée à l'éclosion d'une pandémie ou qui présente le potentiel d'être associée à l'éclosion d'une pandémie, en combinaison avec un adjuvant sous la forme d'une émulsion d'huile dans l'eau comprenant une huile métabolisable, un stérol ou un tocophérol tel qu'un alpha-tocophérol et un agent émulsifiant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83143706P | 2006-07-17 | 2006-07-17 | |
GB0618195A GB0618195D0 (en) | 2006-09-15 | 2006-09-15 | Influenza vaccine |
GB0619090A GB0619090D0 (en) | 2006-09-27 | 2006-09-27 | Influenza vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30624B1 true MA30624B1 (fr) | 2009-08-03 |
Family
ID=37909516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31612A MA30624B1 (fr) | 2006-07-17 | 2009-02-04 | Vaccin anti-grippal |
Country Status (14)
Country | Link |
---|---|
US (4) | US9278127B2 (fr) |
EP (1) | EP2043682B1 (fr) |
JP (1) | JP5639760B2 (fr) |
KR (1) | KR101696727B1 (fr) |
CO (1) | CO6150191A2 (fr) |
CR (1) | CR10559A (fr) |
EA (1) | EA200900024A1 (fr) |
HR (2) | HRP20140488T1 (fr) |
IL (1) | IL196024A0 (fr) |
MA (1) | MA30624B1 (fr) |
MX (1) | MX2009000660A (fr) |
NO (1) | NO20090062L (fr) |
PL (1) | PL2043682T3 (fr) |
WO (1) | WO2008009309A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
PE20061428A1 (es) | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl |
PT2032163E (pt) | 2006-06-15 | 2013-04-11 | Novartis Ag | Regime em multidoses de vacinação de influenza poupador de adjuvante |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
BRPI0909820A2 (pt) | 2008-03-05 | 2015-08-11 | Sanofi Pasteur | Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima |
JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
EP2310045A1 (fr) | 2008-06-25 | 2011-04-20 | Novartis AG | Réactions rapides à des immunisations de rappel retardées |
AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
CA2752039A1 (fr) | 2009-02-10 | 2010-08-19 | Novartis Ag | Regimes de vaccin antigrippal pour souches liees a une pandemie |
CN102946900A (zh) * | 2010-03-11 | 2013-02-27 | 免疫设计公司 | 用于大流行流感的疫苗 |
US20120107354A1 (en) * | 2010-10-30 | 2012-05-03 | George Dacai Liu | Viral vaccine and process for preparing the same |
EP2578974A1 (fr) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Chaîne de traitement pour la production de particules lyophilisées |
GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
EP3055412B1 (fr) | 2013-10-07 | 2020-09-02 | Seqirus UK Limited | Filtre traité |
WO2016012414A1 (fr) | 2014-07-21 | 2016-01-28 | Sanofi Pasteur | Dispositif d'alimentation en liquide pour générer des gouttelettes |
KR101729387B1 (ko) | 2015-04-17 | 2017-04-21 | 경희대학교 산학협력단 | 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 m1-m2-na-ha 바이러스 유사 입자의 제조방법 |
CA2990635A1 (fr) * | 2015-06-24 | 2016-12-29 | Sanofi Pasteur, Inc. | Methodes d'utilisation du vaccin de la grippe pour la prevention de la pneumonie |
GB201710414D0 (en) | 2017-06-29 | 2017-08-16 | Univ Nottingham | Chemotherapy |
WO2019143955A1 (fr) * | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccin inactivé largement protecteur contre le virus de la grippe |
WO2019204507A1 (fr) * | 2018-04-18 | 2019-10-24 | Biomadison, Inc. | Procédés de détermination de l'activité d'un vaccin |
KR102103638B1 (ko) * | 2018-06-01 | 2020-04-22 | 연세대학교 산학협력단 | 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
DK0382271T3 (da) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler som adjuvanser i vacciner |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
US5149531A (en) | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
MY111880A (en) | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
DE4220757A1 (de) | 1992-06-24 | 1994-01-05 | Schering Ag | Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
AU6141094A (en) | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
CN1124013A (zh) | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE280585T1 (de) | 1994-02-24 | 2004-11-15 | Micro Pak Inc | Impfstoffe, die paucilamelläre lipidvesikel als adjuvans enthalten |
WO1995026204A1 (fr) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate |
US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
EP1009382B1 (fr) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Emulsions huile-dans-l'eau contenant des saponines |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
BR9910269A (pt) | 1998-05-07 | 2001-01-09 | Corixa Corp | Composição adjuvante e métodos para seu uso |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
CA2363141C (fr) | 1999-02-26 | 2010-04-06 | Chiron Corporation | Microemulsions a macromolecules et microparticules adsorbees |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
KR100808348B1 (ko) | 2000-01-31 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Hiv에 대한 예방 또는 치료용 면역화를 위한 백신 |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP1201250A1 (fr) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques |
DE60239594D1 (de) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
CA2478930A1 (fr) | 2002-04-01 | 2003-10-16 | Euro-Celtique, S.A. | Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene |
WO2004075829A2 (fr) | 2003-01-30 | 2004-09-10 | Chiron Corporation | Vaccin contre la grippe contenant un adjuvant |
EP1722815A1 (fr) * | 2004-03-09 | 2006-11-22 | Chiron Corporation | Vaccins antigrippaux |
US7330082B2 (en) | 2004-08-23 | 2008-02-12 | Texas Instruments Incorporated | Oscillator system, method of providing a resonating signal and a communications system employing the same |
PE20061428A1 (es) * | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl |
US20090028903A1 (en) | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
JP2009514839A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
BRPI0618254A2 (pt) * | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
EP1945252B1 (fr) * | 2005-11-04 | 2013-05-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccins comprenant des antigènes de surface purifié, préparés à partir de virus influenza élevés en culture cellulaire, adjuvés avec squalène |
CA2628206A1 (fr) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
SI2422810T1 (sl) | 2006-07-17 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Influenčno cepivo |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
BRPI0717219B8 (pt) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
EP2227251A1 (fr) * | 2007-12-06 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Composition contre la grippe |
-
2006
- 2006-10-27 MX MX2009000660A patent/MX2009000660A/es active IP Right Grant
- 2006-10-27 JP JP2009519798A patent/JP5639760B2/ja active Active
- 2006-10-27 EP EP06806620.8A patent/EP2043682B1/fr active Active
- 2006-10-27 WO PCT/EP2006/010439 patent/WO2008009309A1/fr active Application Filing
- 2006-10-27 KR KR1020097003223A patent/KR101696727B1/ko active IP Right Grant
- 2006-10-27 EA EA200900024A patent/EA200900024A1/ru unknown
- 2006-10-27 PL PL06806620T patent/PL2043682T3/pl unknown
-
2008
- 2008-12-18 IL IL196024A patent/IL196024A0/en unknown
-
2009
- 2009-01-06 NO NO20090062A patent/NO20090062L/no not_active Application Discontinuation
- 2009-01-14 CR CR10559A patent/CR10559A/es not_active Application Discontinuation
- 2009-01-15 CO CO09003056A patent/CO6150191A2/es unknown
- 2009-02-04 MA MA31612A patent/MA30624B1/fr unknown
-
2011
- 2011-06-17 US US13/163,002 patent/US9278127B2/en active Active
-
2014
- 2014-05-29 HR HRP20140488TT patent/HRP20140488T1/hr unknown
- 2014-11-19 HR HRP20141122TT patent/HRP20141122T1/hr unknown
-
2016
- 2016-01-15 US US14/996,446 patent/US9943588B2/en active Active
-
2018
- 2018-03-14 US US15/920,519 patent/US10555999B2/en active Active
-
2019
- 2019-12-20 US US16/722,437 patent/US11564984B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HRP20140488T1 (hr) | 2014-07-04 |
CR10559A (es) | 2009-03-20 |
US20190054162A1 (en) | 2019-02-21 |
JP2009543816A (ja) | 2009-12-10 |
JP5639760B2 (ja) | 2014-12-10 |
US9943588B2 (en) | 2018-04-17 |
HRP20141122T1 (hr) | 2015-01-02 |
EP2043682B1 (fr) | 2014-04-02 |
EA200900024A1 (ru) | 2009-06-30 |
NO20090062L (no) | 2009-02-16 |
US9278127B2 (en) | 2016-03-08 |
US10555999B2 (en) | 2020-02-11 |
US20110243987A1 (en) | 2011-10-06 |
US20160256537A1 (en) | 2016-09-08 |
MX2009000660A (es) | 2009-04-08 |
US11564984B2 (en) | 2023-01-31 |
KR20090029851A (ko) | 2009-03-23 |
WO2008009309A1 (fr) | 2008-01-24 |
PL2043682T3 (pl) | 2014-09-30 |
EP2043682A1 (fr) | 2009-04-08 |
IL196024A0 (en) | 2011-08-01 |
CO6150191A2 (es) | 2010-04-20 |
US20200360507A1 (en) | 2020-11-19 |
KR101696727B1 (ko) | 2017-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30624B1 (fr) | Vaccin anti-grippal | |
MA29342B1 (fr) | Nouvelle composition | |
MA30866B1 (fr) | Vaccin | |
MA31381B1 (fr) | Vaccin contre la grippe a emulsion huile dans l'eau | |
MA29601B1 (fr) | Vaccin antipaludeen | |
BRPI0621886A8 (pt) | composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza | |
TW200716165A (en) | Novel vaccine formulations | |
MX2010004271A (es) | Formulaciones de vacuna meningococica. | |
BR0007936A (pt) | Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno | |
MA28035A1 (fr) | Vaccin | |
BRPI0413906A (pt) | composições imunogênicas de hiv, kit e métodos relacionados | |
Potter et al. | Effect of priming on subsequent response to inactivated influenza vaccine | |
Ng et al. | Lipopeptide vaccines illustrate the potential role of subtype‐crossreactive T cells in the control of highly virulent influenza | |
MA32080B1 (fr) | Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1 | |
SG139618A1 (en) | Influenza vaccine | |
SG160386A1 (en) | Novel composition | |
CY1113746T1 (el) | Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ | |
MX2009010963A (es) | Vacuna de influenza de emulsion de aceite en agua. | |
CY1115921T1 (el) | Εμβολιο γριπης | |
UY29429A1 (es) | Composición inmunogénica que contiene virus de la gripe o preparación antígena del mismo, sus usos y procedimientos de preparación. | |
FR3043558B1 (fr) | Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant | |
UY29430A1 (es) | Nuevas composiciones inmunogénicas multivalentes contra la gripe, sus usos y procedimientos de preparación. |